Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Next-generation flow cytometry analysis of clonal bone marrow plasma cells identifies an indolent subset of MGUS

Jón Þórir Óskarsson, Sigrun Thorsteinsdottir, Sæmundur Rögnvaldsson, Andri Ólafsson, Gunnhildur Viðarsdóttir, Elfa Rún Guðmundsdóttir, Elias Eythorsson, Ásbjörn Jónsson, Brynjar Viðarsson, Páll T. Önundarson, Bjarni A. Agnarsson, Margrét Sigurðardóttir, Ingunn Þorsteinsdóttir, Ísleifur Ólafsson, Stephen J. Harding, Brian GM Durie, Thorvardur Jon Love, Sigurdur Y. Kristinsson

Blood Adv (2025) 9 (21): 5455–5459.

https://doi.org/10.1182/bloodadvances.2025017270

Published: 2025

Journal Articles

Impact of body mass index on the prognosis of patients with newly diagnosed Multiple Myeloma

Kevin D Arnold, Krystle L Ong, Gayathri Ravi, Meredith C Wessel, Faith E. Davies, Luciano J. Costa, Ananya Deshpande, Gareth J. Morgan, Brenda M Birmann, Elizabeth E Brown

Blood Adv bloodadvances.2025018024.

https://doi.org/10.1182/bloodadvances.2025018024

Published: 2025

Includes: Supplemental data

Journal Articles

Molecular and immunological determinants of long-term survival in multiple myeloma

Khanmi Kasomva, Kritika Yadav, Siegfried Janz, Binod Dhakal, Sridhar Rao

Blood Adv (2025) 9 (20): 5134–5147.

https://doi.org/10.1182/bloodadvances.2025016829

Published: 2025

Journal Articles

Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.

Parvathi Sudha, Phillip Pham, Wen Niu, Enze Liu, Lin Wang, Gillian Truong, Cameron Ligocki, Ramzi Al-Azzawi, Mallini Surapenini, Steven Bray, Francesco Vetrini, Magdalena Czader, Marwan Tayeh, Kelvin P Lee, Rafat Abonour, Attaya Suvannasankha, Brian A Walker

Blood Adv bloodadvances.2025017721.

https://doi.org/10.1182/bloodadvances.2025017721

Published: 2025

Includes: Supplemental data

Journal Articles

AL Amyloidosis: A Real-World Experience with CAR-T Cell Therapy

Blood Adv bloodadvances.2025017488.

https://doi.org/10.1182/bloodadvances.2025017488

Published: 2025

Includes: Supplemental data

Journal Articles

Ablation of CD38 in Multiple Myeloma Cells Leads to an Aggressive Phenotype in a Mouse Xenograft Model

Michael Riley Dyer, Alexander Zheleznyak, Erin N. Teubner, Julie Prior, Brad Manion, Zhenghan Jing, Amit K. Sharma, Junwei Du, Rui Tang, Mark A Fiala, John F. DiPersio, Deborah Veis, Julie O'Neal, Mikhail Y. Berezin, Monica Shokeen

Blood Adv bloodadvances.2025017296.

https://doi.org/10.1182/bloodadvances.2025017296

Published: 2025

Journal Articles

Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies

Andrew Kowalski, Jill Lykon, Benjamin Diamond, David Coffey, Marcella Kaddoura, Francesco Maura, James Hoffman, Abhishek Pandey, Dickran Kazandjian, Ola Landgren

Blood Adv (2025) 9 (19): 4979–4986.

https://doi.org/10.1182/bloodadvances.2025016911

Published: 2025

Journal Articles

Long-term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101

Michael Sang Hughes, Samuel Pan, Rajshekhar Chakraborty, Jayant Raikhelkar, Mathew S. Maurer, Markus Y. Mapara, Andrew Eisenberger, Suzanne Lentzsch, Divaya Bhutani

Blood Adv (2025) 9 (19): 4946–4950.

https://doi.org/10.1182/bloodadvances.2025016731

Published: 2025

Includes: Supplemental data

Journal Articles

The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia

Asis Shrestha, Sharmilan Thanendrarajan, Aishee Bag, Binod Dhakal, Maurizio Zangari, Samer Al-Hadidi, Frits van Rhee, Anita D’Souza, Nishi Shah, Mansi R. Shah, Meera Mohan, Carolina Schinke

Blood Adv (2025) 9 (19): 4806–4809.

https://doi.org/10.1182/bloodadvances.2025016695

Published: 2025

Journal Articles

Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study

Blood Adv bloodadvances.2025017597.

https://doi.org/10.1182/bloodadvances.2025017597

Published: 2025

Includes: Supplemental data

Journal Articles

Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?

Taku Kikuchi, Ukyo Kondo, Shotaro Sugita, Miyu Watanabe, Chiaki Matsumoto, Moe Nomura-Yogo, Kodai Kunisada, Haruka Sawada, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki, Osamu Hosoya, Tadao Ishida, Nobuhiro Tsukada

Blood Adv (2025) 9 (18): 4716–4719.

https://doi.org/10.1182/bloodadvances.2025017174

Published: 2025

Includes: Supplemental data

Journal Articles

Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels

Rahul Banerjee, Meera Mohan, Kai Rejeski, Benjamin R. Puliafito, Diana D. Cirstea, Gurbakhash Kaur, Shonali Midha, Georgia J. McCaughan, Nikhil M. Kumar, Nikita Mehra, Bhausaheb Bagal, Noopur S. Raje

Blood Adv (2025) 9 (18): 4720–4726.

https://doi.org/10.1182/bloodadvances.2025016490

Published: 2025

Journal Articles

Sequential BCMA CAR T-cell therapy in refractory multiple myeloma

Tim Richardson, Udo Holtick, Jan-Hendrik Frenking, Hishan Tharmaseelan, Hyatt Balke-Want, Ruth Flümann, Elias Karl Mai, Sandra Sauer, Raphael Teipel, Malte von Bonin, Michael Hallek, Christof Scheid, Philipp Gödel

Blood Adv (2025) 9 (18): 4624–4630.

https://doi.org/10.1182/bloodadvances.2025016712

Published: 2025

Journal Articles

Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia

Blood Adv (2025) 9 (18): 4568–4579.

https://doi.org/10.1182/bloodadvances.2025016513

Published: 2025

Journal Articles

Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma

Xian Zhang, Lin Wang, Junfang Yang, Xiaona N. Hu, Hui Wang, Lina N. Zhang, Xiaoge Zhou, Ying Liu, Qinglong Wang, Pei H. Lu

Blood Adv (2025) 9 (18): 4543–4552.

https://doi.org/10.1182/bloodadvances.2025016322

Published: 2025

Includes: Supplemental data

Journal Articles

Progressive NK Cell Dysfunction and ILC Imbalance Favor Immune Evasion in Multiple Myeloma

Maria Teresa Bilotta, Antonio Giovanni Solimando, Prof., Vanessa Desantis, Lucia Di Marzo, Andrea Sabatini, Sergio Forcelloni, Alessandro Andriano, Arcangelo Morizio, Antonella Argentiero, Roberto Ria, Linda Quatrini, Lorenzo Moretta, Paola Vacca, Nicola Tumino

Blood Adv bloodadvances.2025016659.

https://doi.org/10.1182/bloodadvances.2025016659

Published: 2025

Includes: Supplemental data

Journal Articles

Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring

Efstathios Kastritis, Irene Solia, Panagiotis Malandrakis, Foteini Theodorakakou, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Despina Fotiou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Vassiliki Spiliopoulou, Nikoleta Kokkali, Asimina Papanikolaou, Stavroula Giannouli, Maria Gavriatopoulou, Evangelos Terpos, Meletios A. Dimopoulos

Blood Adv (2025) 9 (17): 4444–4447.

https://doi.org/10.1182/bloodadvances.2025016083

Published: 2025

Includes: Supplemental data

Journal Articles

Fifteen year of use of functional imaging in multiple myeloma: where we started from and where are we going

Elena Zamagni, Marco Talarico

Blood Adv bloodadvances.2024015686.

https://doi.org/10.1182/bloodadvances.2024015686

Published: 2025

Journal Articles

Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia

Blood Adv bloodadvances.2025016966.

https://doi.org/10.1182/bloodadvances.2025016966

Published: 2025

Includes: Supplemental data

Journal Articles

Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging

Carolina Schinke, Leo Rasche, Cody Ashby, Rudy van Hemert, Sharmilan Thanendrarajan, Samer Al Hadidi, Maurizio Zangari, Clyde Bailey, Daisy V. Alapat, John D. Shaughnessy, Jr, Fenghuang Zhan, Bart Barlogie, Frits van Rhee, Niels Weinhold

Blood Adv (2025) 9 (17): 4368–4377.

https://doi.org/10.1182/bloodadvances.2025016510

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Next-generation flow cytometry analysis of clonal bone marrow plasma cells identifies an indolent subset of MGUS

Impact of body mass index on the prognosis of patients with newly diagnosed Multiple Myeloma

Molecular and immunological determinants of long-term survival in multiple myeloma

Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.

AL Amyloidosis: A Real-World Experience with CAR-T Cell Therapy

Ablation of CD38 in Multiple Myeloma Cells Leads to an Aggressive Phenotype in a Mouse Xenograft Model

Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies

Long-term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101

The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia

Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study

Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?

Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels

Sequential BCMA CAR T-cell therapy in refractory multiple myeloma

Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia

Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma

Progressive NK Cell Dysfunction and ILC Imbalance Favor Immune Evasion in Multiple Myeloma

Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring

Fifteen year of use of functional imaging in multiple myeloma: where we started from and where are we going

Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia

Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only